KR102319787B1 - Oral biofilm calcification inhibitor and oral composition - Google Patents

Abstract

It has excellent calcification inhibitory effect on oral biofilm and gives high tartar formation inhibitory effect. It provides an oral biofilm calcification inhibitor consisting of an extract of a cherry tree containing caffeoyl glucose or caffeoyl glucose, and a composition for oral use comprising an extract of a cherry tree containing caffeoyl glucose or caffeoyl glucose.

Description

Oral biofilm calcification inhibitor and oral composition {ORAL BIOFILM CALCIFICATION INHIBITOR AND ORAL COMPOSITION}

The present invention relates to an oral biofilm calcification inhibitor and a composition for oral cavity, which has excellent calcification inhibitory effect on oral biofilm, and has a high tartar formation inhibitory effect.

Tartar is a plaque (biofilm) calcified by saliva components or gingival sulcus exudate components, and is considered to be a scaffold to which new plaques are attached, and to aggravate periodontal disease by expanding the periodontal pocket by the growth of calculus. Therefore, tartar removal is very important in the treatment of periodontal disease, and tartar prevention is also important from the viewpoint of periodontal disease prevention. On the other hand, removal of calculus from teeth requires great effort by the operator and pain of the patient, and frequent tartar removal leads to sound grinding of hemorrhoids, causing great damage to hemorrhoids. In these respects, the prevention of tartar formation is of great dental significance.

In recent years, from the viewpoint of inhibiting crystal growth, focusing on the fact that calculus components are formed from crystals of calcium phosphate (mainly hydroxyapatite and dibasic calcium phosphate), various water-soluble condensed phosphates (pyrophosphate, tripolyphosphate, polyphosphate, etc.) of condensed phosphate) and zinc compounds (zinc citrate, zinc chloride) are being developed (Patent Document 1; Japanese Patent Application Laid-Open No. 2008-74773, Patent Document 2; Japanese Patent Application Laid-Open No. 2008-74774).

Japanese Patent Laid-Open No. 2008-74773 Japanese Patent Laid-Open No. 2008-74774 International Publication No. 2011/099570 Japanese Patent Laid-Open No. 2013-75880

However, the prior art approach inhibits the binding (chelating action) with calcium and phosphoric acid in saliva, so it is only a coping therapy in the oral cavity, where calcium and phosphoric acid are constantly abundant, and the fundamental calculus formation suppression technique is development was desired.

The present invention has been made in view of the above circumstances, and it is an object of the present invention to provide an oral biofilm calcification inhibitor and a composition for oral cavity which is excellent in the calcification inhibitory effect on the oral biofilm, and gives a high tartar formation inhibitory effect.

The present inventors have conducted intensive studies to achieve the above object, and as a result, 1-O-(E)-caffeoyl-β-D-glucopyranoside of caffeoyl glucose has excellent calcification inhibitory effect on oral biofilm, and , it was found that the same effect was recognized for the high tartar formation inhibitory effect, and the extract of cherry trees, particularly cherry blossoms, containing the above-mentioned caffeoyl glucose. Moreover, by mix|blending this caffeoyl glucose or the extract of the cherry tree containing this with the composition for oral cavity, the outstanding biofilm calcification inhibitory effect was provided, and it discovered that the markedly high calculus formation inhibitory effect was acquired.

In addition, studies of microorganisms involved in the formation of calculus have been conducted for a long time, and the formation of calculus is recognized as one of biomineralization and has been known for a long time as a biological phenomenon, but calcification of plaque (biofilm) in the process of calculus formation. An evaluation technique based on this has not been established. In this situation, the present inventors have developed an in vitro calculus model (biofilm calcification) that is different from the evaluation model of calculus formation inhibition (Patent Documents 1 and 2) focusing on the conventional chelating action and can also evaluate the metabolic inhibition of microorganisms involved in calculus formation. model) was newly developed, and various components were examined using this in vitro calculus model. As a result, the effect of inhibiting the metabolism of oral bacteria involved in the calcification of the biofilm to caffeoyl glucose, a glycoside of phenylpropanoid, significantly lowers the calcium concentration in the calcified biofilm, and the effect of suppressing the calcification of the biofilm was recognized. The present invention was carried out by discovering that there is a remarkably excellent tartar formation inhibitory effect, and thereby the prevention or suppression of tartar formation beyond the conventional simple coping therapy can be expected.

Patent Document 3 (International Publication No. 2011/099570) discloses that extracts of cherry blossoms or leaves, 1-O-(E)-caffeoyl-β-D-glucopyranoside are terminal glycosylation product production inhibitors, AGE production inhibitors, AGE is proposed to be effective as an inhibitor of apoptosis of fibroblasts by However, it is the new knowledge of the present inventors that caffeoyl glucose exhibits the biofilm calcification inhibitory effect as described above, and is effective in inhibiting calculus formation.

Therefore, the present invention provides the following oral biofilm calcification inhibitor and oral composition.

〔One〕

An oral biofilm calcification inhibitor composed of caffeoyl glucose.

〔2〕

An oral biofilm calcification inhibitor comprising an extract of a cherry tree containing caffeoyl glucose.

[3] The method of [2],

An oral biofilm calcification inhibitor that the extract of cherry tree contains 0.001 mass % or more of caffeoyl glucose.

〔4〕

An oral composition comprising caffeoyl glucose.

[5] The method of [4],

A composition for oral use containing an extract of cherry trees containing caffeoyl glucose.

[6] The method of [5],

A composition for oral use that the extract of cherry tree contains 0.001 mass % or more of caffeoyl glucose.

[7] in [4], [5] or [6],

The composition for oral cavity content of caffeoyl glucose is 0.001-0.2 mass % of the whole composition.

[8] The method according to any one of [4] to [7],

A composition for oral use that is a toothpaste or mouthwash.

[9] The method according to any one of [4] to [8],

An oral composition for inhibiting oral biofilm calcification.

(Effects of the Invention)

According to the present invention, it is possible to provide an oral biofilm calcification inhibitor and a composition for oral cavity excellent in the calcification inhibitory effect on the oral biofilm, and a high calculus formation inhibitory effect. Moreover, prevention or suppression of radical calculus formation beyond simple coping therapy can be expected by this.

Hereinafter, the present invention will be described in more detail. Oral biofilm calcification inhibitor of the present invention is caffeoyl glucose 1-O-(E)-caffeoyl-β-D-glucopyranoside (1-O-(E)-caffeoyl-β-D-glucopyranoside) It contains as an active ingredient. This is a compound represented by the following formula.

In the present invention, an extract containing caffeoyl glucose, specifically, a cherry tree extract may be used as caffeoyl glucose, and this may be used as an active ingredient.

In the present invention, cherry tree (櫻) is a generic term excluding plum, peach, apricot, etc. among plants of the genus Rosaceae, and generally refers to belonging to the subgenus Prunus (Subgen. Cerasus). The species of the cherry tree is not particularly limited, and for example, cherry trees belonging to the wild cherry group, the Japanese cherry tree group, the bean cherry group, the sperm cherry group (Prunus apetala), the wild cherry tree group, the cherry group, the cherry tree group, etc. can be used. , but not limited to these groups.

The part of the cherry tree used for the raw material is preferably leaves or flowers, especially flowers.

A well-known method can be employ|adopted as an extraction method, and solvent extraction, especially solvent extraction using a polar solvent is employable preferably.

Here, when extracting with a polar solvent, a polar solvent is not specifically limited. For example, water, methanol, ethanol, isopropanol, acetone, 1,3-butylene glycol, ethylene glycol, propylene glycol, glycerin, acetic acid, ethyl acetate, and ether are mentioned. You may mix. Among them, lower alcohols having 1 to 3 carbon atoms, such as water, methanol, and ethanol, and alcohols in which these are mixed can be preferably used.

Caffeyl glucose can be prepared by the method described in Patent Document 3 (International Publication No. 2011/099570). Specifically, the following method is mentioned.

An extraction raw material is put into a treatment tank filled with an extraction solvent, and the active ingredient is eluted while stirring. After eluting the active ingredient in a solvent, the extract of a cherry tree is obtained by filtering and removing an extraction residue. Thereafter, the extract is subjected to treatment such as dilution, concentration, drying, and purification according to a conventional method to obtain an extract containing a high concentration of caffeoyl glucose. It is also possible to isolate caffeoyl glucose.

In addition, in the present invention, the extract of cherry tree preferably contains caffeoyl glucose 0.001% or more, particularly 0.02% or more, particularly 2% or more. The upper limit is not particularly limited and may contain 100% of isolated caffeoyl glucose.

A commercial item can also be used as such an extract of a cherry tree. Specific commercially available products include Oryza Oil & Fat Chemical Co., Ltd. Production cherry blossom extract (trade name "SAKURA Extract-P") can be used.

When the oral biofilm calcification inhibitor of the present invention is blended in the composition for oral cavity, the content of caffeoyl glucose is preferably 0.001% (mass%, hereinafter the same) or more of the entire composition in terms of pure content, more preferably 0.02% or more am. Moreover, 0.2 % or less is preferable, More preferably, it is 0.06 % or less from a viewpoint of a usability|use_condition. The more the compounding amount is, the better the biofilm calcification inhibitory effect is, and in order to sufficiently give the biofilm calcification inhibitory effect, it is preferable to blend 0.001% or more. When it exceeds 0.2%, the feeling of use may be affected, and therefore, it is preferable from the viewpoint of feeling of use that it is 0.2% or less.

In addition, the extract of cherry tree can be formulated in the content of the total composition of caffeoyl glucose within the above range. Specifically, the blending amount of the cherry tree extract is preferably 0.05% or more of the total composition, more preferably 1% or more. Moreover, 10 % or less is preferable, More preferably, it is 3 % or less.

The composition for oral use of the present invention can be prepared in various formulations such as toothpaste such as tube toothpaste, toothpaste, liquid toothpaste, mouthwash, gel, ointment, mouth freshener, toothpaste tablet, oral paste, gum massage cream, etc. . In addition to the above essential ingredients, these preparations can be blended with other known ingredients according to the dosage form as needed within a range that does not impair the effects of the present invention, and can be prepared by a conventional method. In particular, it is preferable as a toothpaste and mouthwash, and the toothpaste may further contain an abrasive, a viscous agent, a binder, a surfactant, and if necessary, a flavoring agent, a sweetener, a preservative, an active ingredient, and the like. The mouthwash may further contain a wetting agent, a surfactant, a flavoring agent, a sweetener, a preservative, an active ingredient, and the like, if necessary.

Examples of the abrasive include precipitated silica, silica gel, aluminosilicate, zeolite, zirconosilicate, calcium diphosphate dihydrate and anhydride, calcium pyrophosphate, calcium carbonate, aluminum hydroxide, alumina, magnesium carbonate, magnesium triphosphate, insoluble meta sodium phosphate, insoluble potassium metaphosphate, titanium oxide, hydroxyapatite, synthetic resin-based abrasive, and the like (blending amount; usually 5 to 50% of the total composition). In addition, an abrasive is not normally mix|blended with a mouthwash.

Examples of the viscous agent (wetting agent) include sugar alcohols such as sorbitol, xylitol, maltitol, lactitol, erythritol, palatinose and trehalose, and polyhydric alcohols such as glycerin, propylene glycol, polyethylene glycol, and 1,3-butylene glycol. There is (blended amount; usually 10 to 50% of the total composition).

Examples of the binder include cellulose derivatives such as sodium carboxymethyl cellulose and hydroxyethyl cellulose, alginic acid derivatives such as sodium alginate and propylene glycol alginate, gums such as guar gum, xanthan gum, and gum arabic, carrageenan, gelatin, polyvinyl alcohol, Synthetic binders, such as sodium polyacrylate, carboxyvinyl polymer, and polyvinylpyrrolidone, etc. are mentioned (blending amount; 0.1 to 5% of the whole composition normally).

As surfactant, anionic surfactant, nonionic surfactant, and cationic surfactant can be mix|blended.

Examples of the anionic surfactant include alkyl sulfates such as sodium lauryl sulfate and sodium myristyl sulfate; , hydrogenated coconut fatty acid monoglyceride monosulphate, sodium laurylsulfoacetate, N-acylglutamate such as sodium N-palmitoylglutamate, sodium N-methyl-N-acyltaurine, sodium N-methyl-N-acylalanine , sodium α-olefinsulfonate, and the like.

Examples of the nonionic surfactant include sugar alcohol fatty acid esters such as sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, and sucrose fatty acid ester, glycerin fatty acid ester, polyglycerol fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyethylene glycol fatty acid ester, etc. Ether-type surfactants, such as polyhydric alcohol fatty acid ester, polyoxyethylene alkyl ether, polyoxyethylene polyoxypropylene copolymer, polyoxyethylene alkylphenyl ether, polyoxyethylene hydrogenated castor oil, fatty acid alkanes, such as lauric acid diethanolamide olamide.

Examples of the cationic surfactant include alkylammonium and alkylbenzylammonium salts.

When mix|blending these surfactant, 5% or less of the compounding quantity of the whole composition is preferable, and especially 0.001-5% of it is preferable.

As a perfume component, a well-known perfume usually added, for example, menthol, carbonyl, limonene, n-decyl alcohol, citronellol, α-terpineol, cineol, linalool, ethyl linalool, vanillin, thymol and fragrances such as peppermint oil, spearmint oil, winter green oil, sperm oil, and eucalyptus oil.

Examples of the sweetener include sodium saccharin, stevioside, dipotassium glycyrrhetinate, perillartine, and thaumatin. Examples of the preservative include paraoxybenzoic acid ester, benzoic acid or a salt thereof.

Examples of active ingredients include enzymes such as dextranase, mutanase, lysozyme, amylase, protease, lytic enzyme, superoxide dismutase (SOD), sodium monofluorophosphate, potassium monofluorophosphate, etc. of alkali metal monofluorophosphate, sodium fluoride, fluoride such as stannous fluoride, cetyl pyridinium chloride, benzethonium chloride, benzalkonium chloride, dequalinium chloride, chlorhexidine hydrochloride, chlorhexidine gluconate, triclosan, popidone iodine, Sterilization ingredients such as isopropylmethylphenol and hinokitiol, tranexamic acid, ε-aminocaproic acid, allantoin, dihydrocholesterol, glycyrrhetic acid, glycerophosphate, chlorophyll, sodium chloride, xylitol, zinc chloride, water-soluble inorganic phosphoric acid compound However, vitamins such as vitamin A, vitamin B group, vitamin C, vitamin E, and derivatives thereof may be combined with one type or two or more types. In addition, the compounding quantity of these active ingredients can be made into an effective amount in the range which does not interfere with the effect of this invention.

It is preferable to adjust and maintain the composition for oral cavity of this invention to pH 5-9 using a pH adjuster, and more preferable pH is 6-8.

Examples of the pH adjuster include inorganic acids such as hydrochloric acid, phosphoric acid and boric acid, organic acids such as lactic acid and citric acid, sodium hydroxide, potassium hydroxide, alkylamines such as triethylamine, tripropylamine, and trilaurylamine, monoethanolamine, diethanolamine , triethanolamine, diisopropanolamine, tripropanolamine, triisopropanolamine, ethyldiethanolamine, alkanolamines such as trometamol, various amines such as N-methylpiperidine, potassium hydrogenphosphate, sodium hydrogenphosphate, etc. Organic salts, such as a phosphate, sodium citrate, and sodium lactate, etc. are mentioned. The amount of the pH adjuster can be appropriately selected depending on the set pH.

(Example)

Hereinafter, although an Example, a comparative example, and a formulation example are shown and this invention is demonstrated concretely, this invention is not limited to a following example. In addition, in the following examples, all represent mass % unless otherwise stated.

[Example, Comparative Example]

The biofilm calcification inhibitory effect was evaluated by the method shown as an experimental example below using the chemical|medical agent (test composition) shown in a table|surface. The results are written together in the table.

Experimental Example: Test of biofilm calcification inhibitory effect

The bacteria used were purchased from the American Type Culture Collection and pre-cultured by the following method.

Actinomyces viscosus ATCC43146, Fusobacterium nucleatum ATCC10953, Porphyromonas gingivalis ATCC33277 5mg/L hemin (manufactured by Sigma) and 1mg/L It culture|cultivated with the Todd-Hewitt medium (made by Becton and Dickinson) culture solution [THBHM] containing L vitamin K (made by Wako Pure Chemical Industries, Ltd.). Veillonella parvula ATCC17745 was cultured in a Todd-Hewitt medium (manufactured by Becton and Dickinson) containing 1.26% sodium lactate (manufactured by Sigma) in a culture medium [THBL]. In addition, the culture was anaerobic (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen) overnight at 37°C. After incubation, the bacterial solution was collected by centrifugation (8,000 g x 10 min). Each of the centrifuged bacteria was resuspended in the Basal medium mucin culture solution [BMM] ^*1 .

A hydroxyapatite (HA) plate (Asahi Optical Co., Ltd.) having a diameter of 7 mm x a thickness of 3.5 mm was treated with human non-irritating saliva filtered through a 0.45 μm filter, and used as a carrier for model production, 24 holes It was installed at the bottom of a multi-plate (made by Sumitomo Bakelite Co., Ltd.). The above 4 strains prepared in BMM at 1×10 ⁷ cfu/mL (cfu: colony forming units) were seeded, and cultured at 37° C. under anaerobic conditions (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen) for 2 days. and a biofilm of a mixture of 4 strains was formed on the HA surface.

Then, after removing the culture solution, the test composition shown in the table was added, treatment was performed for 3 minutes, washed with PBS (manufactured by Wako Pure Chemical Industries, Ltd.), and then replaced with a ^{calcification induction medium *2.} The same sample treatment was performed every 24 hours, and cultured for 5 days under anaerobic conditions (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen) at 37 ° C., and the biofilm of a mixture of 4 species on the HA surface was calcified.

The obtained calcified biofilm was recovered by dispersing from the HA surface by ultrasonication (200 μA, 10 seconds). The amount of calcium in the calcified biofilm (pmol) was measured using a Hitachi Polarized Zeeman Atomic Absorption Spectrophotometer Z-5310 (manufactured by Hitachi High-Technologies Corporation).

The biofilm calcification inhibition rate of the test composition with respect to the control (physiological saline) was calculated|required by the following formula from the said measurement result. In addition, in the control (physiological saline), as shown in the table, the amount of calcium in the calcified biofilm was 204 pmol.

Biofilm calcification inhibition rate (%)

= {(Amount of calcium in calcified biofilm of control (pmol))-(Amount of calcium in calcified biofilm of test composition (pmol))}/(Amount of calcium in calcified biofilm of control (pmol))

The biofilm calcification inhibitory effect was evaluated based on the following criteria.

Evaluation standard

◎: Biofilm calcification inhibition rate of 80% or more

○: Biofilm calcification inhibition rate 70% or more and less than 80%

△: Biofilm calcification inhibition rate of 50% or more and less than 70%

×: biofilm calcification inhibition rate less than 50%

*1 Composition of BMM: It is expressed by the mass in 1 liter.

proteose peptone

(manufactured by Becton and Dickinson) 4g/L

tryptone

(manufactured by Becton and Dickinson) 2g/L

East Extract

(manufactured by Becton and Dickinson) 2g/L

Mucin (manufactured by Sigma) 5g/L

Hemin (manufactured by Sigma) 2.5mg/L

Vitamin K (manufactured by Wako Pure Chemical Industries, Ltd.) 0.5mg/L

KCl (manufactured by Wako Pure Chemical Industries, Ltd.) 1 g/L

Cysteine (manufactured by Wako Pure Chemical Industries, Ltd.) 0.2 g/L

distilled water remainder

(The volume was increased so that the total amount was 1L and autoclaved at 121°C for 20 minutes)

*2 Composition of calcification induction medium: It is expressed by mass in 1 liter.

Calcium chloride (manufactured by Wako Pure Chemical Industries, Ltd.) 0.22 g/L

Sodium chloride (manufactured by Wako Pure Chemical Industries, Ltd.) 0.14 g/L

Potassium chloride (manufactured by Wako Pure Chemical Industries, Ltd.) 0.75 g/L

Sodium dihydrogen phosphate dihydrate (manufactured by Wako Pure Chemical Industries, Ltd.) 0.12 g/L

Sodium hydrogen phosphate dodecahydrate (manufactured by Wako Pure Chemical Industries, Ltd.) 1.22 g/L

Sodium bicarbonate 1.85g/L

Magnesium sulfate heptahydrate (manufactured by Wako Pure Chemical Industries, Ltd.) 0.04 g/L

BMM rest

(The volume was increased so that the total amount was 1L, and autoclaved at 121°C for 20 minutes)

From the results of Table 1, it can be seen that caffeoyl glucose or cherry blossom extract exerts a biofilm calcification inhibitory effect, and can provide an excellent calculus formation inhibitory effect. In addition, the composition of Examples is suitable for use because there is no problem in the feeling of use.

The details of the raw materials to be used are shown below.

· Caffeyl glucose (*3) was obtained by the following method according to the method described in Patent Document 3 (International Publication No. 2011/099570) was used.

A cherry blossom extract obtained by solvent extraction of flowers of a cherry tree (Prunus lannesiana Wils. cv. Sekiyama) was attached to column chromatography (HP-20 column chromatography), and an aqueous elution section, a methanol elution section and acetone were applied. An elution was obtained. The obtained methanol elution part was repeatedly separated and purified using normal phase silica gel column chromatography, reverse phase ODS column chromatography and HPLC, and caffeoyl glucose (1-O-(E)-caffeoyl-β-D-glucopyranoside) was isolated.

· For the cherry blossom extract (*4), Oryza Oil & Fat Chemical Co., Ltd. SAKURA Extract-P (caffeoyl glucose content 2.0%) was used.

Hereinafter, a prescription example is shown. The details of the raw material to be used are the same as described above. As a result of evaluating these formulation examples similarly to the above, the biofilm calcification inhibitory effect was exhibited and it was excellent in the calculus formation inhibitory effect.

[Prescription Example 1] Toothpaste

Aluminum hydroxide 45.0%

Gelling Silica 2.0

Sorbit (70% aqueous solution) 25.0

Carboxymethylcellulose sodium 1.0

Sucrose Monopalmitate 1.0

Sodium Lauryl Sulfate 1.0

Saccharin Sodium 0.2

Ethanol 0.1

Sodium Benzoate 0.1

thymol 0.05

SAKURA Extract-P (manufactured by Oryza Oil & Fat Chemical Co., Ltd.) 1.0

(caffe oil glucose content 0.02%)

Sodium Malate 1.0

Spices 1.0

Proper amount of hydrochloric acid or sodium hydroxide

water balance

Total 100.0%

[Prescription Example 2] Toothpaste

Aluminum hydroxide 45.0%

Gelling Silica 2.0

Sorbit (70% aqueous solution) 25.0

Carboxymethylcellulose sodium 1.0

Sucrose Monopalmitate 1.0

Sodium Lauryl Sulfate 1.0

Saccharin Sodium 0.2

Ethanol 0.1

Sodium Benzoate 0.1

thymol 0.05

Caffeyl Glucose ^{* 3} 0.05

Xylitol 10.0

Spices 1.0

Proper amount of hydrochloric acid or sodium hydroxide

water balance

Total 100.0%

[Prescription Example 3] Toothpaste

Isopropylmethylphenol 0.05%

Sodium Lauryl Sulfate 1.5

Lauroylsarcosine Sodium 0.1

Polyoxyethylene (20) sorbitan monostearic acid ester 0.6

Erythritol 20.0

Caffeyl Glucose ^{* 3} 0.03

Propylene Glycol 3.0

Carboxyvinyl Polymer 0.6

xanthan gum 0.6

Saccharin Sodium 0.2

Sodium Fluoride 0.21

Sodium hydroxide 0.15

Silicic anhydride 22.0

Spices 1.2

water balance

Total 100.0%

[Formulation Example 4] Mouthwash

Ethanol 18.0%

Polyoxyethylene (60) hydrogenated castor oil 2.0

Glycerin 10.0

Palmitoylsarcosine sodium 0.1

citric acid 0.01

Trisodium citrate 0.3

Cetylpyridinium Chloride 0.05

SAKURA Extract-P (manufactured by Oryza Oil & Fat Chemical Co., Ltd.) 0.5

(caffe oil glucose content 0.01%)

Farnesol 0.05

Sodium Tartrate 1.0

spice 0.5

0.1% Green No. 201 0.8

Proper amount of hydrochloric acid or sodium hydroxide

water balance

Total 100.0%

[Formulation Example 5] Mouthwash

Ethanol 20.0%

Polyoxyethylene (60) hydrogenated castor oil 2.0

Glycerin 10.0

Palmitoylsarcosine sodium 0.1

citric acid 0.01

Trisodium citrate 0.3

Cetylpyridinium Chloride 0.05

Xylitol 10.0

Caffeyl Glucose ^{* 3} 0.05

Farnesol 0.05

Sodium Tartrate 1.0

spice 0.5

0.1% Green No. 201 0.8

Proper amount of hydrochloric acid or sodium hydroxide

water balance

Total 100.0%

[Formulation Example 6] Oral paste

Hydroxyethyl Cellulose 3.0

Carrageenan 1.0

Sorbit (70% aqueous solution) 40.0

Sucrose Palmitic Acid Monoester 2.0

Lauroylsarcosine Sodium 0.3

Aluminum lactate 0.8

Saccharin Sodium 0.1

Trehalolipid 0.02

Sodium Tartrate 1.0

SAKURA Extract-P (manufactured by Oryza Oil & Fat Chemical Co., Ltd.) 3.0

(caffe oil glucose content 0.06%)

Spices 1.0

Proper amount of hydrochloric acid or sodium hydroxide

water balance

Total 100.0%

Claims (9)

An oral biofilm calcification inhibitor containing 0.001 to 0.2 mass% of caffeoyl glucose. An oral biofilm calcification inhibitor comprising an extract of a cherry tree containing 0.001 to 0.2 mass% of caffeoyl glucose. 3. The method of claim 2,
An oral biofilm calcification inhibitor that the extract of cherry tree contains 0.02 to 0.2 mass % of caffeoyl glucose. An oral composition comprising 0.001 to 0.2 mass% of caffeoyl glucose. 5. The method of claim 4,
An oral composition containing an extract of cherry tree containing caffeoyl glucose. 6. The method of claim 5,
The extract of the cherry tree is an oral composition comprising 0.02 to 0.2% by mass of caffeoyl glucose. delete 7. The method according to any one of claims 4 to 6,
A composition for oral use that is a toothpaste or mouthwash. 7. The method according to any one of claims 4 to 6,
An oral composition for inhibiting oral biofilm calcification.